Alternative Data for Ligand Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 92 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,588 | Sign up | Sign up | Sign up |
| X Followers | 10,408 | Sign up | Sign up | Sign up |
| X Mentions | 9 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 56 | Sign up | Sign up | Sign up |
| Linkedin Employees | 131 | Sign up | Sign up | Sign up |
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
| Price | $211.48 |
| Target Price | Sign up |
| Volume | 167,001 |
| Market Cap | $4.23B |
| Year Range | $113.76 - $221.24 |
| Dividend Yield | 0% |
| PE Ratio | 34.63 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $239February 23 - Benzinga |
|
Ligand Pharmaceuticals: 2026 Guidance May Already Be Included In Current ValuationJanuary 27 - SeekingAlpha |
|
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
 |
Earnings Scheduled For February 26, 2026February 25 - Benzinga |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 115M | 25M | 91M | 117M | 149M | 3.090 |
| Q2 '25 | 48M | 2.9M | 45M | 4.8M | 21M | 1.600 |
| Q1 '25 | 45M | 4.8M | 40M | -42M | -41M | 1.330 |
| Q4 '24 | 43M | 2.8M | 40M | -31M | -30M | 1.270 |
| Q3 '24 | 52M | 12M | 39M | -7.2M | 3.4M | 1.840 |
Insider Transactions View All
| Espinoza Octavio filed to sell 34,333 shares at $200.1. March 6 '26 |
| Reardon Andrew filed to sell 41,369 shares at $200.6. March 6 '26 |
| Espinoza Octavio filed to sell 31,320 shares at $203.6. March 6 '26 |
| Espinoza Octavio filed to sell 31,988 shares at $202.8. March 6 '26 |
| Espinoza Octavio filed to sell 33,635 shares at $201.1. March 6 '26 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Gilbert Cisneros |
Feb 16, 26 | Buy | $1K - $15K |
| Gilbert Cisneros |
Feb 16, 26 | Buy | $1K - $15K |
Read more about Ligand Pharmaceuticals (LGND) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Ligand Pharmaceuticals
The Market Cap of Ligand Pharmaceuticals is $4.23B.
As of today, Ligand Pharmaceuticals' PE (Price to Earnings) ratio is 34.63.
Currently, the price of one share of Ligand Pharmaceuticals stock is $211.48.
The LGND stock price chart above provides a comprehensive visual representation of Ligand Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ligand Pharmaceuticals shares. Our platform offers an up-to-date LGND stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Ligand Pharmaceuticals (LGND) does not offer dividends to its shareholders. Investors interested in Ligand Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Ligand Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
